Skip to main content
Advertising

Originally published December 17, 2013 at 10:36 AM | Page modified December 18, 2013 at 7:01 AM

  • Share:
             
  • Comments (0)
  • Print

Pfizer, Teva reach deal to allow generic Viagra

Pfizer Inc. has reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.


Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

Pfizer Inc. has reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

Pfizer said Tuesday that Teva will pay an undisclosed royalty for a license to produce a generic version of Viagra, one of New York-based Pfizer's best-selling drugs. Viagra generated about $1.14 billion in U.S. sales last year and more than $2 billion worldwide.

Pfizer's patent protecting Viagra from generic competition expires in April 2020, but Teva Pharmaceuticals USA Inc. will be allowed to launch its generic version in the United States on Dec. 11, 2017. Teva Pharmaceuticals USA is a division of Israeli-based Teva Industries Ltd.

Pfizer Inc. had sued Teva in 2010 over the drugmaker's plans to introduce a generic version of Viagra. Drugmakers fight to protect patents because sales of their drugs plunge after cheaper, generic competition enters the market.

For instance, Pfizer lost U.S. patent protection for the cholesterol fighter Lipitor, which was once the world's top-selling drug, in November 2011. U.S. revenue from that drug plummeted from $5 billion in 2011 to about $932,000 last year.

Other drugmakers also are dealing with a wave of patent expirations that have hurt their revenue. The patent protecting another erectile dysfunction drug, Eli Lilly and Co.'s Cialis, also expires in 2017.

Shares of Pfizer fell 8 cents to $30.17 in Tuesday afternoon trading, while the Standard & Poor's 500 index also dropped slightly. U.S.-traded shares of Teva climbed 16 cents to $39.88.



News where, when and how you want it

Email Icon

Free Shipping!

Free Shipping!

Do some holiday shopping in The Seattle Times Store until Monday, 12/1 and your order qualifies for free shipping.

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►